<DOC>
	<DOCNO>NCT03081234</DOCNO>
	<brief_summary>This international , multi-center , randomize , double-blinded , placebo-controlled clinical study evaluate efficacy safety ribociclib endocrine therapy adjuvant treatment patient hormone receptor-positive , HER2-negative , intermediate risk breast cancer .</brief_summary>
	<brief_title>Adjuvant Ribociclib With Endocrine Therapy Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer</brief_title>
	<detailed_description>While adjuvant endocrine therapy ( ET ) effective reduce risk recurrence patient hormone receptor ( HR ) -positive early breast cancer ( EBC ) , recurrence still common , especially patient unfavorable clinical , pathological and/or molecular feature . Ribociclib , CDK4/6 inhibitor , demonstrate clinical efficacy tolerable toxicity add ET patient HR-positive , HER2-negative advance breast cancer . The purpose study evaluate effect addition ribociclib standard adjuvant ET invasive disease-free survival patient HR+ , HER2- intermediate-risk EBC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Key Histologically confirm unilateral primary invasive adenocarcinoma breast Estrogen receptorpositive and/or progesterone receptorpositive , HER2negative breast cancer Patient surgical resection tumor tumor remove completely surgical specimen microscopic margin free tumor available archival tumor tissue surgical specimen Patient AJCC 8th edition Prognostic Stage Group II Patient complete adjuvant radiotherapy ( indicate ) accord institutional guideline prior screen Patient may already initiate adjuvant endocrine therapy ( ET ) time randomization , randomization must take place within 52 week date initial histological diagnosis breast cancer within 12 week initiate ET ECOG Performance Status 0 1 Adequate bone marrow organ function Sodium , potassium , phosphorus , magnesium total calcium laboratory value within normal limit QTcF interval &lt; 450 msec mean rest heart rate 5090 bpm Key Prior neoadjuvant therapy ( endocrine therapy chemotherapy ) CDK4/6 inhibitor Prior treatment tamoxifen , raloxifen aromatase inhibitor reduction risk ( chemoprevention ) breast cancer and/or treatment osteoporosis within last 2 year Patient inflammatory breast cancer Prior treatment anthracyclines cumulative dos 450 mg/m² doxorubicin 900 mg/m² epirubicin Distant metastasis breast cancer beyond regional lymph node Patient recover clinical laboratory acute toxicity chemotherapy , radiotherapy surgery Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality , clinically significant cardiac arrhythmia Uncontrolled hypertension systolic blood pressure &gt; 160 mmHg Patient currently receive prohibit substance discontinue 7 day prior Cycle 1 Day 1 : concomitant medication , herbal supplement , and/or fruit juice know strong inhibitor inducer CYP3A4/5 ; medication narrow therapeutic window predominantly metabolize CYP3A4/5 ; systemic corticosteroid ≤ 2 week prior start study drug , fully recover side effect treatment ; concomitant medication know risk prolong QT interval and/or know cause torsades de point discontinue replaced safe alternative medication . Pregnant breastfeeding ( lactate ) woman woman plan become pregnant breastfeed study Women childbearing potential unless use highly effective method contraception study treatment 21 day stop study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hormone receptor-positive</keyword>
	<keyword>Estrogen and/or progesterone receptor-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Intermediate risk early breast cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Ribociclib</keyword>
	<keyword>LEE011</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>Endocrine therapy</keyword>
	<keyword>Phase III</keyword>
	<keyword>breast carcinoma</keyword>
	<keyword>breast cancer</keyword>
</DOC>